Dosing Optimization of Ampicillin-Sulbactam Based on Cystatin C in Elderly Patients with Pneumonia. 2021

Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University.

Ampicillin-sulbactam is a first-line therapy for pneumonia and is mainly excreted by the kidney. It is important to optimize the dose and dosing interval of ampicillin-sulbactam because in patients with decreased renal function and low skeletal muscle mass, such as the elderly, excess drug may burden renal function. In this study, we evaluated indices of renal function and optimized the dose and dosing interval of ampicillin-sulbactam based on pharmacokinetics (PK) and pharmacodynamics theory in elderly patients. The serum concentrations of ampicillin and sulbactam were measured by HPLC, and PK parameters were calculated. Correlations between the clearance of ampicillin or sulbactam and renal function were evaluated, and dosing optimization was calculated based on PK parameters. The PK parameters of ampicillin were CL = 6.5 ± 4.0 L/h, Vd = 19.3 ± 0.2 L, Ke = 0.4 ± 0.2, and t1/2 = 2.7 ± 1.6 h. The most correlated renal function index was estimated glomerular filtration rate (eGFRcys-c) calculated by serum cystatin-c (r = 0.7374, correlation formula; CL of ampicillin = 0.1937 × eGFRcys-c-0.6726). Based on this formula, we calculated the clearance of ampicillin and developed dosing regimens for the elderly. Serum cystatin-c concentration is an ideal index to optimize ampicillin-sulbactam antimicrobial therapy in elderly patients with pneumonia.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
February 2014, Infection,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
January 2015, Biological & pharmaceutical bulletin,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
April 2021, Pharmacology research & perspectives,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
June 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
August 2016, International journal of clinical pharmacy,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
December 1998, The Japanese journal of antibiotics,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
January 2006, Internal medicine (Tokyo, Japan),
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
December 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
June 2021, Pharmaceutical research,
Kayoko Matsubara, and Kazuaki Matsumoto, and Yuta Yokoyama, and Erika Watanabe, and Yuki Enoki, and Akari Shigemi, and Kazuro Ikawa, and Hideyuki Terazono, and Norifumi Morikawa, and Tamao Ohshige, and Yasuo Takeda
December 2023, Journal of critical care,
Copied contents to your clipboard!